Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 3/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL593309 | 0.89 | CYP2C8 (0.51) | BACE1CYP2C8DHODHAPPRXRA | |
| SCHEMBL7041867 | 0.84 | BACE1 (0.44) | BACE1MEN1MAPTHTTRAB9A | |
| SCHEMBL30755410 | 0.84 | BACE1 (0.44) | BACE1MEN1MAPTHTTRAB9A | |
| SCHEMBL23354520 | 0.83 | RXRA (0.51) | BACE1CYP2C8DHODHAPPRXRA | |
| SCHEMBL31676846 | 0.83 | RXRA (0.51) | BACE1CYP2C8DHODHAPPRXRA | |
| SCHEMBL23354270 | 0.83 | IL2 (0.49) | BACE1CYP2C8DHODHAPPKIF11 | |
| SCHEMBL22703438 | 0.82 | TDP1 (0.46) | DHODHAKR1C3MEN1RAB9AKMT2A | |
| SCHEMBL27371068 | 0.81 | APP (0.43) | BACE1DHODHAPPRXRAMEN1 | |
| SCHEMBL29485413 | 0.81 | FOLH1 (0.53) | MEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL3229734 | 0.81 | FOLH1 (0.53) | MEN1KMT2ATDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114993-B2 | Use of aryl chlorides in palladium-catalyzed C-H bond functionalization | THE UNIVERSITY OF HOUSTON SYSTEM (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114993-B2 | Use of aryl chlorides in palladium-catalyzed C-H bond functionalization | THE UNIVERSITY OF HOUSTON SYSTEM (US) | 2012-02-14 | — | — | US | disclosed |
| US-20090012293-A1 | USE OF ARYL CHLORIDES IN PALLADIUM-CATALYZED C-H BOND FUNCTIONALIZATION | THE UNIVERSITY OF HOUSTON SYSTEM (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012293-A1 | USE OF ARYL CHLORIDES IN PALLADIUM-CATALYZED C-H BOND FUNCTIONALIZATION | THE UNIVERSITY OF HOUSTON SYSTEM (US) | 2009-01-08 | — | — | US | disclosed |
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012293-A1 | USE OF ARYL CHLORIDES IN PALLADIUM-CATALYZED C-H BOND FUNCTIONALIZATION | DBH, DDT, CYCS | BACE1 4452/4885CYP2C8 77/4885DHODH 226/4885 |
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | BACE1 49/4885CYP2C8 710/4885DHODH 4355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.